Vaccines and Immunotherapy (VAC)

Advancing Vaccines and Immunotherapies to Combat Infectious Diseases and Malignancies

Antibodies to Fight against Microbial Pathogens

Innovations Targeting Adaptive Immune Mechanisms against Viral Pathogens

Late-breaking: Vaccines and Immunotherapy

Next-Generation Adjuvants and Vaccine Design

Novel Platforms Enhancing Vaccine Delivery and Efficacy

Targeting Adaptive Immune Responses against Cancer and Other Pathologies

(819) BCG vaccine induced CD4 T cell activation is dependent on processing by cDC1 and cDC2 subsets of human dendritic cells.

(822) Germline-targeting vaccine elicits HIV broadly neutralizing antibodies in nonhuman primates

(823) A Non-Invasive Dissolvable Microneedle Platform for Liposome-Encapsulated rBmHAXT(ΔCys) Delivery Against Lymphatic Filariasis

(824) Therapeutic potential of bovine type III interferon (IFN-λ3) as anti-bovine viral diarrhea virus agent

(825) Exosomal tetraspanin (EXT)-Based Exosome Engineering

(826) SOCS1 Antagonist Inhibits SARS-like Virus Mediated Cell Death

(827) “Next-Generation Mpox Vaccine: Enhancing MVA-Based Immunity Through PD-1 Checkpoint Modulation "​

(828) Vaccine Literacy in a Misinformation Era: Implications for Education and Public Trust

(829) HARNESSING THE POTENTIAL OF mRNA VACCINES AGAINST HEPATITIS C VIRUS

(830) Context and Stage-specific Effects of Nr4a in CD8 T cell Immunity

(831) Exploring the antiviral potency of synthetic Cationic lipo-oligopeptides (CLOPs) against Herpes simplex virus type 1

(832) Intranasal exposure to SARS-CoV-2 spike protein induces Th2 and Th17 cell‐associated pulmonary immunopathology

(833) Design and Evaluation of a Novel Recombinant Antigen for a T Cell-Based Vaccine Against Valley Fever

(833) Vaccination Consolidation: Dual-Engineered Vaccine Confers Protection against Yersinia pestis and Burkholderia pseudomallei Aerosol Challenge

(834) Indoleamine 2,3-dioxygenases-isoforms in the host anti-tuberculous immunity and vaccine response

(834) Protective Immunity after DNA Vaccination against Pneumonic Plague Using a Needle-Free Jet Injection Platform

(835) Amino-bisphosphonates enhance CD8⁺ T cell responses to vaccine antigens through an ATRAID-dependent mechanism involving the stromal compartment

(835) Overcoming Immunodominance by A Nanoparticle Adjuvant for Universal Influenza Vaccine Development

(836) Antigen processing of Mycobacterium bovis BCG vaccine substrains differs in mouse dendritic cells

(836) CYP1B1 Inhibitor Chlorprothixene Increased Survival Rate of Cigarette Smoke-exposed Mice in Lethal IAV Infection.

(837) A Tetravalent Dengue prM-E mRNA-LNP Vaccine Protects via Antibodies in Susceptible Mice

(837) Population Density, Vaccination Coverage, and the Persistent Burden of Influenza Mortality in the United States

(838) Distinct Humoral Response Development to Measles Virus across Vaccine Platforms

(838) Hypertensive Mice Display Decreased Antibody Responses to COVID-19 Vaccination

(839) Development of an NS1-based dengue vaccine that protects via non-neutralizing antibodies and evades antibody-dependent enhancement

(839) Optimizing immunity against toxoplasmosis by using extracellular vesicles released from Toxoplasma gondii and infected host immune cells

(840) Carbohydrate-Modified Virus-Like Particles as a Vaccine Platform for Leishmania braziliensis

(840) HSP interaction with individual CD91 ligand binding domains

(841) Exploiting Virus-like Particles (VLP)-Peptide Platforms to Target SA-85 Trans-Sialidase for Chagas Disease Immunotherapy

(841) Structural characterization of antibodies binding the conserved central helix and membrane-proximal lower stalk of coronavirus spike glycoprotein

(842) A Bispecific VHH-IgA Fusion Antibody Confers Broad Protection Against Enterotoxigenic Escherichia coli

(842) Development of a safe and effective nanoparticle-based vaccine against porcine epidemic diarrhea virus

(843) Development of a Human Lymphatic Filariasis Vaccine, LFGuard for Clinical Testing

(843) Structural Characterization of the Human West Nile Virus Antibody Response

(844) Impact of mRNA COVID-19 Vaccination on Immunometabolic Profiles in Patients with Lymphoid Malignancies

(844) Sustained Humoral Activation through self-amplifying mRNA Vaccination Enhances Longitudinal Antibody Function in a Phase III Trial

(845) Boosting with Heterologous Vaccines against SARS-CoV-2 Broadens the Cross-Immunity to β-Coronaviruses

(846) Design and Generation of a DEC-205–Targeted Single Chain Variable Fragment (scFv) for Directed Delivery of West Nile Virus Antigen

(846) Homogenously-sized chlamydial nanovaccine efficiently activates dendritic cells by caveolin endocytosis to boost innate immune responses

(847) Development of a Novel Mucosal Vaccine Against Clostridium difficile

(847) Structural characterization of broadly neutralizing and potent V1/V2 apex antibodies elicited in rhesus macaques through immunization

(848) Green-synthesized gold nanoparticles derived from Spirulina and Leptolyngbya, modulate innate immune response via M1 polarization of THP-1 macrophages

(848) Monoclonal antibody therapy for rabies disease: long term impact on central nervous system recovery

(849) Antibody-mediated intracellular neutralization as a correlate of risk for rotavirus gastroenteritis in vaccinated infants

(849) Development of a mucosal vaccine for pan-Sarbecoviruses: a papilloma pseudovirus expressing SARS-CoV-2 M and N proteins

(850) Complex intra-host SARS-CoV-2 evolution following monoclonal antibody pre-exposure prophylaxis

(850) Mucosal vaccination clears Clostridioides difficile colonization

(851) Defining the contribution of breast milk immunoglobulins to infant immunity.

(852) A Multidonor Plasma Antibody Class with Broad Activity Against H5N1 Neuraminidase

(852) Natural Chlamydia trachomatis Immunity Highlights CPAF as a Key Vaccine Target

(853) Monoclonal antibody therapy promotes survival by recalibrating neuroinflammation during Australian Bat Lyssavirus Infection

(854) Bacterial bunker-busters: Novel Immunotherapeutics against Pneumonic Plague

(854) Fusion Peptide Priming and Trimer Boosting Strategies for HIV Vaccine Development in Guinea Pigs

(855) Development & clinical validation of microneutralization assays for the robust quantification of neutralizing antibodies to human cytomegalovirus.

(855) Optimized LNP-encapsulated IVT mRNA as a robust platform for the development of next-generation cancer immunotherapies

(856) Cardiac glycosides activate non-canonical STAT1 signaling to reprogram antigen-presenting cells

(857) A bacterial immunotherapeutic drives long-term immunity in Glioblastoma.

(858) Evaluating the Hia adhesin as a potential vaccine antigen against Nontypable Haemophilus influenzae

(859) Conserved Human CD4 T Cell Targets Inform Group A Streptococcus Vaccine Design

(860) A bivalent multi-adjuvant Chlamydia vaccine targeting secreted and outer membrane antigens reduces genital infection and pathology in mice

(861) TH17 responses elicited by a BcfA-containing vaccine protects against B. bronchiseptica disease and respiratory tract bacterial burden in mice

(862) Is Toll-like Receptor 4 Required for Antibody Production?: Using Genetically Defined Mouse Models to Settle the Dispute

(863) Targeting NRAS-Derived Public Neoantigens in T Cell-Based Cancer Immunotherapy

(864) Strategic deletion of genes in BCG leads to an enhancement in immunogenicity

(865) Conserved moonlighting protein pyruvate dehydrogenase induces robust protection against Staphylococcus aureus infection

(866) Cancer vaccine in combination with radiopharmaceutical therapy (RPT) upregulates type I interferon pathway in Ovalbumin-expressing tumor model

(874) Immunomodulatory Tr1 CD4 T cells induced by engineered V1-deleted HIV vaccine candidate decrease the risk of SIV acquisition in macaques

(875) Inhibition of HIV-1 cell-to-cell transmission in-vitro using engineered CAR NK/T cells.

(876) Monoclonal antibody therapy augments production of virus-specific CD4 T cells during Australian bat lyssavirus infection of the CNS

(877) Identification of human T-cell cytomegalovirus epitopes and their conservation across the herpes virus family

(878) Strategically leveraging Influenza A induced trained immunity to shape immune profiles to subsequent vaccination with heterologous antigens

(879) Experimental Validation of Variant Antibodies Guided by a Large Language Model and Optimized through Combinatorial Algorithms

(880) Identification of correlates of HIV-1 Neutralizing Antibodies through a systems serology approach

(881) Engineered TCR therapy targeting lipid antigens in AML

(882) An antigen-less pro-vaccine to treat amyotrophic lateral sclerosis

(883) Long-term maintenance of CD8+ tissue resident memory T cells in the upper respiratory tract

(884) Immunophenotyping of T-cell Responses from Immunocompromised Hosts in Response to Vaccination

(885) Antigen specific T cell responses and cytokine production in healthy subjects following a recombinant hepatitis E vaccine

(886) Integrating in silico Humanization and DNA Delivery to engineer anti-Influenza Monoclonal Antibodies for improved in vivo expression

(888) Assessing Antibody-Mediated Protection Against Acinetobacter baumannii Infection Induced by Multi-Epitope Vaccines AMEV2 & AMEV7

(889) Impact of Pre-Existing Adenovirus Immunity on Vaccine Immunity Induced by ChAdOx1 nCoV-19 in Immunodeficient Patients

(890) Cyclodextrin-Based Nano-Immunotherapy Enhances Dendritic Cell Activation to Drive Anti-Tumor Immunity in Bladder Cancer

(891) Intranasal SARS-CoV-2 vaccine boosting alters immune imprinting and B cell repertoire

(892) Contribution of Influenza H5 Head and Stalk Domains to the Development of Functional Non-Neutralizing Antibodies Following Mucosal rH5-NE Vaccination

(893) Comparison of transcriptional signatures in human and non-human primates during malaria sporozoite vaccination with concurrent chemoprophylaxis

(894) Immunogenicity of Double-Stranded RNA in mRNA Vaccines and its Impact on Immune Cell Function

(895) The adjuvant effect of an Il12 mRNA-LNP reveals a role for CD4+ T cell-dependent DC licensing in the CD8+ T cell response to mRNA vaccination

(896) Design and evaluation of engineered MyD88 fusion proteins for enhancing CAR-T therapy

(898) Development of Single-Administration Burkholderia pseudomallei Vaccines using Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) Technology

(899) Identification of latanoprost as an effective vaccine adjuvant

(900) Nanoparticle delivery amplifies the adjuvant effects of TLR agonists for cancer vaccines

(901) Targeting NK Cell Trafficking and Function with Novel Oral Adjuvant to Enhance HIV Vaccine Efficacy

(902) Co-adjuvants of IFN-γ and a TLR agonist delivered by lipid-PLGA hybrid nanoparticles enhanced the efficacy of an oxycodone vaccine

(903) CpG-Adjuvanted Heplisav-B Induces Strong Th1-Biased Innate Responses Compared to Alum-Adjuvanted HBV Vaccines in PLWH

(904) NanoSTING@Mn Reprograms Aged Lung Immunity to Unleash the Potential of Universal Influenza Vaccines

(905) Dual-Adjuvanted Meningococcal OMVs C Vaccine: Functionality and Cross-Reactive IgG in BALB/c Mice

(906) Understanding the impact of polyethylene glycol (PEG)-lipids on mRNA-LNP vaccine immunogenicity

(907) Low dosage of a novel SARS-COV-2 mRNA-VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine

(908) Rapid protection from lethal Orthopoxvirus infection following vaccination with mRNA-LNP encoding the Type I Interferon Binding Protein.

(909) Skin Immunization With ALFQ-Adjuvanted SARS-CoV-2-Spike Ferritin Nanoparticles Induces Broad and Durable Immunity in Young and Aged Mice

(910) Induction of Robust Immunity Against Hepatitis C Virus Using Rationally Adjuvanted Microneedle Patches Integrating A Secreted Form of E1E2 Heterodimer

(911) Mucosal vaccination with TLR9 agonists promote the development of tissue resident helper cells and mucosal humoral immunity against influenza

(912) Subunit Vaccination Using Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) Platform Elicits Enhanced Humoral and Cellular Immune Responses

(913) QS-21 Modulates Macrophage Activation Through Synergistic Crosstalk with Pattern Recognition Receptors

(914) PLA-PEG-encapsulated Chlamydia muridarum MOMP triggers strong innate immune responses alone and when adjuvanted with the mucosal dmLT in macrophages

(915) Mechanisms of mRNA lipid nanoparticle vaccines in enhancing the immunogenicity of conventional influenza and protein subunit vaccines

(916) TLR2/TLR7 Conjugated Adjuvant Enhances Anti-Nucleoprotein Immunity and Provides Protection Against Lethal H1N1 Influenza Infection

(917) Influenza mRNA-LNP vaccines enhance the immunogenicity of protein-based influenza subunit and inactivated split vaccines after co-administration

(918) Boosting Neonatal Immunity: Zymosan-Adjuvanted Intranasal Bivalent Vaccine Shields Against Lethal EV-A71 and EV-D68 Infections

(919) Nasal anti-CD3 modulates T cell and Microglia activation in aged mice

(920) Modulation of the bone marrow landscape by vaccine adjuvants

(921) A STING-agonist Conjugate Vaccine Potently Synergizes with admixed QS-21 liposomes and CpG to Elicit Robust Th1 Immunity against Chlamydia in mice